Medicare Coverage for GLP-1 Drugs Starts July 1, Transforming $100B Market
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
medicareglp1
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Starting July 1, 2026, Medicare beneficiaries will gain access to prescription weight-loss drugs for the first time in the program's 61-year history. This policy shift directly affects over 67 million people enrolled in Medicare Parts B and D. Marketwatch reported the change on June 24, 2026. The decision unlocks a total addressable market exceeding $100 billion, expanding coverage beyond the 1.9 million commercial users of these drugs in 2025.
The Medicare program has excluded weight loss drug coverage since its 1965 inception, classifying obesity as a cosmetic condition. The last significant expansion of Medicare's drug benefit occurred with the 2003 Medicare Modernization Act, which created Part D. That law added prescription drug coverage for seniors but maintained the obesity exclusion.
Current healthcare spending pressure made this change inevitable. Annual U.S. spending on chronic obesity-related conditions surpassed $400 billion in 2025. Medicare alone bore roughly $125 billion of those costs. The catalyst for reversal was the 2023 FDA approval of GLP-1 drugs like Wegovy and Zepbound for weight management.
These drugs demonstrated significant reductions in cardiovascular events in major clinical trials. Medicare's actuaries now project net cost savings from covering these pharmaceuticals. The Congressional Budget Office revised its 10-year scoring model in 2025 to reflect these long-term healthcare savings, removing the final fiscal barrier to coverage.
The financial magnitude of this policy is substantial. The U.S. weight loss drug market was valued at $24 billion in 2025. Analysts at Barclays project it will reach $100 billion by 2030, with Medicare patients now contributing an estimated 30-40% of that growth.
| Market Segment | 2025 Users | 2026E Post-Coverage Users | Growth |
|---|---|---|---|
| Commercial | 1.9M | 3.5M | 84% |
| Medicare | 0 | 1.8-2.5M | ∞ |
| Total Addressable | 1.9M | 5.3-6.0M | 179-216% |
Current list prices for these drugs range from $1,000 to $1,500 per month. Medicare's negotiated discounts typically range from 25% to 40% off list price. Novo Nordisk's Wegovy holds a 52% U.S. market share in the GLP-1 obesity segment.
Eli Lilly's Zepbound commands 36% market share. Both companies have announced plans to increase production capacity by over 200% by 2027. The S&P 500 Pharmaceuticals Index is up 15% year-to-date, outperforming the broader SPX index's 8% gain.
Direct beneficiaries are the dominant GLP-1 manufacturers. Novo Nordisk (NVO) and Eli Lilly (LLY) are positioned for immediate revenue acceleration. Analysts at JPMorgan estimate Medicare coverage adds $8-12 billion in annual revenue for Novo Nordisk by 2028. Eli Lilly could see a $6-9 billion annual revenue uplift.
Second-order beneficiaries include pharmacy benefit managers (PBMs) like Cigna's Express Scripts (CI) and UnitedHealth's OptumRx (UNH). These entities manage drug formularies and will process the surge in claims. Medical device companies focused on bariatric surgery, such as Intuitive Surgical (ISRG), face a countervailing headwind.
The primary limitation is supply constraint. Both Novo Nordisk and Eli Lilly have struggled to meet existing demand, with intermittent shortages reported since 2024. Medicare's sudden demand injection of 1.8-2.5 million new patients will exacerbate these shortages.
Positioning data from Bloomberg shows hedge funds have been net buyers of NVO and LLY shares for six consecutive weeks. Options flow indicates heavy call buying in the October 2026 expiry cycles. Short interest in medical device stocks tied to obesity interventions has increased by 15% over the same period.
The next catalyst is the July 15, 2026, release of the Medicare Advantage benchmark rates for 2027. These rates will reflect the first actuarial calculations incorporating GLP-1 drug costs. Any significant adjustment will signal the program's long-term cost assumptions.
Monitor the Q2 2026 earnings calls for NVO on August 7 and LLY on August 14. Management commentary on production capacity and gross margin guidance will be critical. The FDA's advisory committee meets on September 10 to review oral GLP-1 formulations, which could further expand the treatment landscape.
Key levels to watch include NVO stock holding above its 200-day moving average of $145. A sustained break above $160 would confirm the bullish trend. For LLY, the $950 level represents major technical resistance. A close above that would target the $1,000 psychological barrier.
Medicare Part D plans have a standard benefit design with a deductible, an initial coverage phase, a coverage gap, and catastrophic coverage. For 2026, the deductible is $545. After meeting the deductible, beneficiaries typically pay 25% coinsurance during the initial coverage phase. For a $1,300 monthly drug, this equates to roughly $325 per month. Many Medicare Advantage plans offer supplemental benefits that may further reduce these costs, but formularies and tier placements will vary significantly by plan.
The Medicare coverage of Viagra in 1998 followed a different pathway. Viagra was approved for a medical condition (erectile dysfunction) and was covered under Part B initially as an injectable medication. The 2003 Medicare Modernization Act later moved it to Part D. The GLP-1 coverage is groundbreaking because it reverses a six-decade exclusion for obesity treatment. The financial scale is also incomparable; the annual market for erectile dysfunction drugs peaked at around $5 billion, while GLP-1s for obesity are projected to be 20 times larger.
The initial coverage determination applies specifically to FDA-approved glucagon-like peptide-1 (GLP-1) receptor agonists for chronic weight management. This includes semaglutide (Wegovy) and tirzepatide (Zepbound). Older weight-loss drugs like phentermine are not covered under this new policy. Medicare requires a diagnosis of obesity or overweight with at least one weight-related comorbidity, such as hypertension or type 2 diabetes. Coverage also requires participation in a comprehensive behavioral weight management program, as stipulated by the FDA's Risk Evaluation and Mitigation Strategy for these drugs.
Medicare's July 1 policy pivot transforms obesity care and unleashes a multi-billion dollar demand surge for dominant GLP-1 manufacturers.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.